NU-0129, based on the spherical nucleic acid platform, is an siRNA drug designed to target the GBM oncogene Bcl2Like12 (Bcl2L12), which can cross the blood–brain barrier and may be a new precision medicine approach for GBM treatment. This evidence concerns the gene BCL2L12 and glioblastoma.